Veru has announced the first patient enrolment in its Phase IIb PLATEAU study, which will evaluate the combination of enobosarm, an oral selective androgen receptor modulator (SARM), and semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1) drug for obesity in older adults. The trial will include around 200 participants aged 65 years or older with a body mass index of at least 35. The main outcome is the percentage change from baseline in total body weight at 68 weeks. Key secondary endpoints for the study include changes in total fat mass, total lean mass, physical function, and patient-reported outcomes for HbA1c and insulin resistance. Veru's CEO, Mitchell Steiner, believes that the next generation of obesity drugs should be combination therapy with GLP-2.